Lack of effect of mild or moderate hepatic impairment on the pharmacokinetics of rimonabant.

被引：0
|
作者：
Grandison, Monica K. [1 ]
Kanamaluru, Vanaja [1 ]
Bishai, Raafat [1 ]
Lockwood, Graham [1 ]
Newton, John [1 ]
机构：
[1] Sanofi Aventis, Malvern, PA USA
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2007年 / 47卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
74
引用
收藏
页码：1199 / 1199
页数：1
相关论文
共 50 条
  • [1] Lack of Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Telavancin
    Goldberg, Michael R.
    Wong, Shekman L.
    Shaw, Jeng-Pyng
    Kitt, Michael M.
    Barriere, Steven L.
    [J]. PHARMACOTHERAPY, 2010, 30 (01): : 35 - 42
  • [2] Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Ozanimod
    Zhang, Peijin
    Hosein, Fareeda
    Yu, Kyungha
    Walker, Susan
    Syto, Mary
    Tirucherai, Giridhar
    Murthy, Bindu
    Tatosian, Daniel
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S843 - S843
  • [3] EFFECT OF MILD AND MODERATE HEPATIC IMPAIRMENT ON QUIZARTINIB PHARMACOKINETICS
    Zahir, H.
    Lasseter, K.
    Marbury, T.
    Rondon, J.
    Bermudez, Y.
    Gammon, G.
    Kamel, Y. Mostafa
    Said, N.
    Hsu, C.
    Abutarif, M.
    Zheng, M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S20 - S20
  • [4] Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam
    Kletzl, Heidemarie
    Ajmi, Hassan
    Antys, Izabela
    Heinig, Katja
    Jaber, Birgit
    Marbury, Thomas C.
    Young, Annie
    Gunther, Andreas
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (08) : 3749 - 3759
  • [5] Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Ozanimod
    Zhang, Peijin
    Hosein, Fareeda
    Yu, Kyungha
    Walker, Susan
    Syto, Mary
    Tirucherai, Giridhar
    Murthy, Bindu
    Tatosian, Daniel
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 976 - 976
  • [6] THE EFFECT OF MILD TO MODERATE HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF ALISPORIVIR (ALV)
    Kovacs, S. J.
    Ke, J.
    Praestgaard, J.
    Barve, A.
    Zhang, J.
    Maietta, R.
    Sunkara, G.
    Stein, D. S.
    [J]. JOURNAL OF HEPATOLOGY, 2013, 58 : S345 - S345
  • [7] Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics and Safety of Carisbamate
    Moore, Kenneth
    Zannikos, Peter
    Solanki, Bhavna
    Greenspan, Andrew
    Verhaeghe, Tom
    Brashear, H. Robert
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (05): : 738 - 746
  • [8] Effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat
    Khosravan, R
    Grabowski, B
    Mayer, M
    Wu, JT
    Joseph-Ridge, N
    Vernillet, L
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (09): : 1083 - 1083
  • [9] Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
    Tortorici, Michael A.
    Toh, Melvin
    Rahavendran, S. V.
    LaBadie, Robert R.
    Alvey, Christine W.
    Marbury, Thomas
    Fuentes, Ernesto
    Green, Matthew
    Ni, Grace
    Hee, Brian
    Pithavala, Yazdi K.
    [J]. INVESTIGATIONAL NEW DRUGS, 2011, 29 (06) : 1370 - 1380
  • [10] Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
    Schnell, David
    Buschke, Susanne
    Fuchs, Holger
    Gansser, Dietmar
    Goeldner, Rainer-Georg
    Uttenreuther-Fischer, Martina
    Stopfer, Peter
    Wind, Sven
    Petersen-Sylla, Marc
    Halabi, Atef
    Koenen, Ruediger
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (02) : 267 - 275
12345